Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
PHASE2CompletedINTERVENTIONAL
Enrollment
64
Participants
Timeline
Start Date
November 30, 2006
Primary Completion Date
September 30, 2007
Conditions
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG
sunitinib malate
Given PO
Trial Locations (2)
10065
Memorial Sloan Kettering Cancer Center, New York
60606
Cancer and Leukemia Group B, Chicago
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | Biotech Hunter | Biotech Hunter